reviewed april 2026|next review october 2026|88 physicians psi has verified|22 published studies
Cartalax
Cartalax is a synthetic tripeptide (alanyl-glutamyl-aspartic acid) from the Khavinson bioregulatory medicine program, classified as a cartilage bioregulator with one of the thinnest evidence bases on this platform (22 published studies).
Evidence landscape: 22 published studies
22 published items. 2 human studies and 17 animal studies.
- 2 Human
- 17 Animal
- 3 Reviews
Not FDA-approved. Not evaluated by any Western regulatory agency. Cartalax is a research compound from the Khavinson bioregulatory program with one of the thinnest evidence bases on this platform.
Not available through Western pharmaceutical channels. Available through Russian supplement and research channels. Part of the Khavinson bioregulator series.
Cartalax (Ala-Glu-Asp) is the cartilage-targeted peptide in the Khavinson organ-specific bioregulator series. 22 published studies, 2 involving humans. The claim that a tripeptide can selectively target cartilage tissue and modulate chondrocyte gene expression has not been substantiated by independent research.
PSI Assessment
Among the Khavinson bioregulatory peptides, cartalax has one of the thinnest evidence bases: 22 published studies, 2 involving humans. The tripeptide (Ala-Glu-Asp) is classified as the cartilage bioregulator in the organ-specific series, proposed to support chondrocyte function during aging. The claim that a tripeptide can selectively target cartilage tissue and modulate chondrocyte gene expression has not been substantiated by independent research. No independent laboratory has published a replication of any cartalax finding.
22 published studies, 2 involving humans. A cartilage bioregulator from the Khavinson program with one of the thinnest evidence bases on this platform.
The proposed mechanism is epigenetic modulation of chondrocyte gene expression to support cartilage matrix production during aging. Cartalax (Ala-Glu-Asp) is the cartilage-targeted peptide in the Khavinson organ-specific bioregulator series. The claim that a tripeptide can selectively target cartilage tissue and modulate chondrocyte gene expression has not been substantiated by independent research.
What the evidence supports
The Khavinson research group reports that cartalax modulates chondrocyte gene expression in cell culture studies. The tripeptide structure (Ala-Glu-Asp) is characterized. Part of a broader bioregulatory program with internally consistent methodology.
What is not yet established
Independent replication of any cartalax finding. Whether the peptide produces measurable cartilage effects in any model outside the originating laboratory. Whether tripeptide-DNA interactions occur as proposed. Clinical relevance for any joint condition.
Research Evidence
The findings below cover the limited evidence base for cartalax, including the proposed mechanism and evidence limitations.
Evidence by condition
Evidence dimensions available for each condition Cartalax has been studied for.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Cartilage Maintenance | ||||
| Joint Health/Aging | ||||
| Chondroprotection |
The Khavinson research group reports that cartalax (Ala-Glu-Asp) modulates chondrocyte gene expression in cell culture studies. 22 published studies exist, 2 involving humans.
No independent laboratory has replicated any cartalax finding. The evidence base is among the thinnest of any compound on this platform.
2 Human|17 Animal|3 Reviews
View all 22 indexed studiesHow Cartalax Works
Cartalax (Ala-Glu-Asp) is a synthetic tripeptide from the Khavinson bioregulatory program. The proposed mechanism is epigenetic modulation of chondrocyte gene expression to support cartilage matrix production. This mechanism has not been independently validated.
A three-amino-acid peptide from the Khavinson program proposed to support cartilage cell health and slow age-related cartilage breakdown.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Ala-Glu-Asp tripeptide. Proposed to modulate chondrocyte gene expression, promoting extracellular matrix synthesis. Khavinson laboratory data.
What is Cartalax being studied for?
Researchers are studying Cartalax across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Cartalax overall. This means a compound can have human studies for one condition but only animal data for another.
Cartilage Maintenance
·Animal StudiesKhavinson research group reports chondrocyte gene expression modulation by cartalax in cell culture and animal models.
Limitations: No independent replication. Whether the peptide reaches cartilage tissue after systemic administration is not established.
Joint Health/Aging
·PreclinicalProposed application for age-related joint degeneration. The Khavinson program classifies cartalax as a cartilage bioregulator.
Limitations: No clinical data for any joint condition. The osteoarthritis application is entirely theoretical.
Chondroprotection
·PreclinicalCell culture studies from the Khavinson laboratory report effects on extracellular matrix protein expression in chondrocytes.
Limitations: In vitro findings only. No animal model data demonstrating cartilage protection in vivo from independent groups.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not evaluated by any Western regulatory agency. One of the least-studied compounds on this platform.
Availability: Not available through Western pharmaceutical channels. Available in Russia through supplement channels.
Class context: Cartalax is a Khavinson bioregulator tripeptide (Ala-Glu-Asp). Low molecular weight suggests minimal toxicity risk. Limited published safety data from any source.
Cartalax has limited published safety data. As a simple tripeptide, toxicity risk is expected to be low. No significant safety concerns have been reported in the limited published literature.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Cartalax discussion.
Comparison and Related Research
Cartalax is the cartilage-targeted peptide in the Khavinson program. The comparisons below provide context against established chondroprotective compounds.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.A study examining how short peptides, including cartalax (AED), influence chondrogenic differentiation of stem cells. The research demonstrated that cartalax modulated expression of genes involved in cartilage formation and extracellular matrix production in cell culture models.Linkova N et al., 2023 in Int J Mol Sci. View on PubMed
- 2.A systematic review covering published evidence on short peptide-DNA interactions and gene expression regulation across the Khavinson bioregulatory peptide series. The review included data on cartalax (AED) and proposed mechanisms by which this tripeptide may influence cartilage-related gene expression.Khavinson VK et al., 2021 in Molecules. View on PubMed
- 3.A preclinical study evaluating the effects of organ-specific peptide regulators, including the cartilage-targeted peptide cartalax (AED), on bone tissue in aging rats. The results suggested that peptide bioregulator administration partially preserved bone structural integrity during aging.Povorozniuk VV et al., 2007 in Adv Gerontol. View on PubMed
- 4.A key reference from the Khavinson bioregulatory program reporting multi-year clinical observations with organ-specific peptides. While focused on thymic and pineal peptides, the paper established the clinical framework within which cartilage-targeted bioregulators like cartalax were subsequently developed and tested.Khavinson VKh et al., 2003 in Neuro Endocrinol Lett. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.